melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Therapeutic Areas
Safety Assessment
 
 

theraTRACE

Melior Pharmaceuticals

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery neurology

MPTP - Induced Parkinson's Disease
MPTP is a potent and selective nigrostriatal dopaminergic neurotoxin that in mice produces many of the neuropathological features of idiopathic Parkinson’s Disease in humans.  MPTP produces nigrostriatal dopaminergic degeneration and locomotor impairment.  Pharmacological agents that increase dopaminergic function or that block the neurotoxicity of MPTP also attenuate MPTP-associated locomotor and dopaminergic dysfunction.  Moreover, MPTP-mediated toxicity may have some relationship to the mechanisms associated with dopaminergic loss in the disease indicating that this model may also be potentially useful for identifying agents that slow or reduce nigrostriatal dopaminergic loss.              

After four days of treatment, mice treated with MPTP exhibit significantly reduced levels of dopamine (A) and number of rears compared to control animals.  L-Deprenyl attenuates rearing activity, exhibiting no significant changes from untreated animals (B).  Data are mean ± SEM; **p<0.01, ***p<0.001 compared to untreated control animals.

 

If you are interested in learning more about MPTP, please contact models@meliordiscovery.com to start the conversation today.